(Las Vegas Nevada United States),DelveInsight’s ”Borderline Personality Disorders – Pipeline Insight, 2023,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Borderline Personality Disorders pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Borderline Personality Disorders Pipeline Report
- Over 5+ Companies and 5+ Pipeline Drugs for Borderline Personality Disorders are in various stages of development, and their anticipated acceptance in the Borderline Personality Disorders market would significantly increase market revenue.
- Leading Borderline Personality Disorders companies developing novel drug candidates to improve the Borderline Personality Disorders treatment landscape include Oryzon, Boehringer Ingelheim, Otsuka, Intra-Cellular Therapies, and others.
- Promising Borderline Personality Disorders pipeline therapies in various stages of development include Vafidemsta and others.
Borderline Personality Disorders Overview
The term ‘Borderline Personality Disorder’ (BPD) refers to a psychiatric syndrome that is characterized by emotion dysregulation, impulsivity, risk-taking behavior, irritability, feelings of emptiness, self-injury, and fear of abandonment, as well as unstable interpersonal relationships. Paranoid ideation and dissociative states are also transient features of the syndrome. Moreover, many patients with BPD show recurring self-injurious or suicidal behavior. BPD has a lifetime prevalence of about 6%. It is much more common in clinical settings, thus rendering BPD highly relevant for health care providers and public health in general.
Borderline Personality Disorders Pipeline Analysis: Drug Profile
Vafidemstat: Oryzon
Vafidemstat (ORY-2001) is an oral small molecule that has been optimized for CNS indications and that acts as a covalent inhibitor of the epigenetic enzyme Lysine Specific Demethylase-1, LSD1 (KDM1A). Oryzon has performed a Phase IIa clinical trial (REIMAGINE study) to assess vafidemstat’s effects on agitation-aggression in patients with different psychiatric disorders: Autism Spectrum Disorder (ASD), Borderline Personality Disorder (BPD) and adult Attention Deficit Hyperactivity Disorder (ADHD).
Discover more about the emerging Borderline Personality Disorders drugs @ Borderline Personality DisordersTreatment Drugs
Borderline Personality Disorders Pipeline Therapies and Key Companies
- Vafidemstat: Oryzon
And many others
Borderline Personality Disorders Pipeline Therapeutics Assessment
This segment of the report provides insights about the Borderline Personality Disorders drugs segregated based on the following parameters that define the scope of the report, such as:
DelveInsight’s Report covers around 5+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
Borderline Personality Disorders pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
Molecule Type
Products have been categorized under various Molecule types such as
- Small molecule
- Cell Therapy
- Peptides
- Polymer
- Small molecule
- Gene therapy
Product Type
Drugs have been categorized under various product types like Mono, Combination, and Mono/Combination.
Scope of the Borderline Personality Disorders Pipeline Report
- Coverage: Global
- Key Borderline Personality Disorders Companies: Oryzon, Boehringer Ingelheim, Otsuka, Intra-Cellular Therapies, and others.
- Key Borderline Personality Disorders Pipeline Therapies: Vafidemsta and others
Find out more about the Borderline Personality Disorders treatment options in development @ Borderline Personality Disorders Clinical Trials
Table of Contents
1. Borderline Personality Disorders Introduction
2. Borderline Personality Disorders Executive Summary
3. Borderline Personality Disorders Overview
4. Borderline Personality Disorders Pipeline Therapeutics
5. Borderline Personality Disorders Late-Stage Products (Phase III)
6. Borderline Personality Disorders Mid-Stage Products (Phase II)
7. Borderline Personality Disorders Early Stage Products (Phase I/II)
8. Borderline Personality Disorders Preclinical Stage Products
9. Borderline Personality Disorders Discovery Stage Products
10. Borderline Personality Disorders Therapeutic Assessment
11. Borderline Personality Disorders Inactive Products
12. Borderline Personality Disorders Collaborations Assessment- Licensing / Partnering / Funding
13. Borderline Personality Disorders Unmet Needs
14. Borderline Personality Disorders Market Drivers and Barriers
15. Appendix
16. About DelveInsight
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services